Invesaro

Stocks Comparison

RxSight vs Staar Surgical: revenue, profit, margins and growth compared

RxSight brought in $134.5M of revenue in fiscal 2025, Staar Surgical $239.4M in fiscal 2025. Revenue changed by -3.9% at RxSight and -23.7% at Staar Surgical on the year before, so RxSight grew faster. RxSight kept -29.0% of its revenue as net profit, Staar Surgical -33.6%. Free cash flow was -$19.3M at RxSight and -$40.1M at Staar Surgical.

Side by side, latest fiscal year

RXSTSTAA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (January 2, 2026)
Revenue$134.5M$239.4M
Revenue growth-3.9%-23.7%
Net income-$38.9M-$80.4M
Net margin-29.0%-33.6%
Free cash flow-$19.3M-$40.1M
Free cash flow margin-14.4%-16.7%
Earnings per share (diluted)-$0.95-$1.62
Cash$19.9M$153.2M
Debtn/an/a
Price to earningsn/an/a
Market value$193.8M$1B
Dividend yieldn/an/a
Rank by revenue in sector#279 of 523 · Health care#239 of 523 · Health care

Over the years

Revenue
RXST FY2021: $14.7MRXST FY2021: $22.6MRXST FY2022: $49MRXST FY2023: $89.1MRXST FY2024: $139.9MRXST FY2025: $134.5MSTAA FY2018: $124MSTAA FY2019: $150.2MSTAA FY2020: $163.5MSTAA FY2021: $230.5MSTAA FY2022: $239.4MSTAA FY2023: $322.4MSTAA FY2024: $313.9MSTAA FY2025: $239.4MFY18FY19FY20FY21FY22FY23FY24FY25
RXST $134.5MSTAA $239.4M
Net income
RXST FY2021: $27.6MRXST FY2021: -$48.7MRXST FY2022: -$66.8MRXST FY2023: -$48.6MRXST FY2024: -$27.5MRXST FY2025: -$38.9MSTAA FY2018: $5MSTAA FY2019: $14MSTAA FY2020: $5.9MSTAA FY2021: $27.5MSTAA FY2022: $39.7MSTAA FY2023: $21.3MSTAA FY2024: -$20.2MSTAA FY2025: -$80.4MFY18FY19FY20FY21FY22FY23FY24FY25
RXST -$38.9MSTAA -$80.4M
Net margin
RXST FY2021: 187.9%RXST FY2021: -215.5%RXST FY2022: -136.2%RXST FY2023: -54.6%RXST FY2024: -19.6%RXST FY2025: -29.0%STAA FY2018: 4.0%STAA FY2019: 9.4%STAA FY2020: 3.6%STAA FY2021: 11.9%STAA FY2022: 16.6%STAA FY2023: 6.6%STAA FY2024: -6.4%STAA FY2025: -33.6%FY18FY19FY20FY21FY22FY23FY24FY25
RXST -29.0%STAA -33.6%
Revenue growth
RXST FY2021: +53.9%RXST FY2022: +116.9%RXST FY2023: +81.8%RXST FY2024: +57.1%RXST FY2025: -3.9%STAA FY2019: +21.2%STAA FY2020: +8.8%STAA FY2021: +41.0%STAA FY2022: +3.9%STAA FY2023: +34.7%STAA FY2024: -2.6%STAA FY2025: -23.7%FY19FY20FY21FY22FY23FY24FY25
RXST -3.9%STAA -23.7%
Free cash flow
RXST FY2021: -$37.7MRXST FY2021: -$46.6MRXST FY2022: -$61.2MRXST FY2023: -$46.4MRXST FY2024: -$22.4MRXST FY2025: -$19.3MSTAA FY2018: $10.5MSTAA FY2019: $15.7MSTAA FY2020: $12.5MSTAA FY2021: $30.3MSTAA FY2022: $17.6MSTAA FY2023: -$3.6MSTAA FY2024: -$7.7MSTAA FY2025: -$40.1MFY18FY19FY20FY21FY22FY23FY24FY25
RXST -$19.3MSTAA -$40.1M

Fiscal years as each company reports them; the two may end in different months.

Questions about RxSight and Staar Surgical

Which is bigger by revenue, RxSight or Staar Surgical?

Staar Surgical is bigger by revenue: $239.4M in fiscal 2025, against $134.5M for RxSight in fiscal 2025.

Which keeps more of its revenue as profit, RxSight or Staar Surgical?

RxSight had a net margin of -29.0% in fiscal 2025; Staar Surgical had -33.6% in fiscal 2025.

Which grew revenue faster, RxSight or Staar Surgical?

In their latest fiscal years revenue changed by -3.9% at RxSight and -23.7% at Staar Surgical.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies